ArticleJournal of medicinal chemistry2017
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Article
- Atroposelective Synthesis of Biaryl N-Oxides via Cu-Catalyzed De Novo Heteroaromatic N-Oxide Ring Formation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Synthesis of Selenium-DecoratedThe Journal of organic chemistry · 2024Article
- Medicinal Chemistry of Drugs withJournal of medicinal chemistry · 2024Review
- Synthesis and Characterization of New N-acyl Hydrazone Derivatives of Carprofen as Potential Tuberculostatic Agents.Antibiotics (Basel, Switzerland) · 2024Article
- Recent Methods for the Synthesis of Quinoxaline Derivatives and their Biological Activities.Mini reviews in medicinal chemistry · 2024Review
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis throughFrontiers in microbiology · 2024Article
- Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.Pharmaceutics · 2023Review
- The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.Nature reviews. Chemistry · 2023Review
- Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide-Hydrazone and Thiadiazole Derivatives Targeting InhA.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Water-Soluble Salts Based on Benzofuroxan Derivatives-Synthesis and Biological Activity.International journal of molecular sciences · 2022Article
- Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria.Biomedicines · 2022Article
- Structural Rigidification ofACS medicinal chemistry letters · 2022Article
- Quinoxaline Moiety: A Potential Scaffold againstMolecules (Basel, Switzerland) · 2021Review
- Design, synthesis and biological evaluation of N-oxide derivatives with potent in vivo antileishmanial activity.PloS one · 2021Article
- Molecule Property Analyses of Active Compounds forJournal of medicinal chemistry · 2020Review
- Improving the Potency ofACS medicinal chemistry letters · 2020Article
- The quest for the holy grail: new antitubercular chemical entities, targets and strategies.Drug discovery today · 2020Review
- Anti-Molecules (Basel, Switzerland) · 2018Article
- A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused byFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Guilherme Felipe Dos Santos FernandesSão Paulo State University (UNESP) , Institute of Chemistry, Araraquara 14800060, Brazil.ORCID 0000-0002-7644-5466
Paula Carolina de SouzaSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Elsa Moreno-ViguriUniversidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain.ORCID 0000-0001-6302-6230
Mery Santivañez-VelizUniversidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain.
Rocio PaucarUniversidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain.
Silvia Pérez-SilanesUniversidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical, Pamplona 31008, Spain.ORCID 0000-0002-6284-4546
Konstantin ChegaevDipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy.ORCID 0000-0001-9962-1218
Stefano GuglielmoDipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy.ORCID 0000-0002-3313-4369
Loretta LazzaratoDipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy.ORCID 0000-0001-7100-8593
Roberta FrutteroDipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino , Turin 10124, Italy.
Chung Man ChinSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Patricia Bento da SilvaSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Marlus ChorilliSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.ORCID 0000-0002-6698-0545
Mariana Cristina SolciaSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Camila Maríngolo RibeiroSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Caio Sander Paiva SilvaSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Leonardo Biancolino MarinoSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Priscila Longhin BosquesiSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Debbie M HuntMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute , 1 Midland Road, London NW1 1AT, United Kingdom.
Luiz Pedro S de CarvalhoMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute , 1 Midland Road, London NW1 1AT, United Kingdom.
Carlos Alberto de Souza CostaSão Paulo State University (UNESP) , School of Odontology, Araraquara 14801903, Brazil.
Sang Hyun ChoInstitute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States.
Yuehong WangInstitute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States.
Scott Gary FranzblauInstitute of Tuberculosis Research, University of Illinois at Chicago , Chicago, Illinois 60607, United States.
Fernando Rogério PavanSão Paulo State University (UNESP) , School of Pharmaceutical Sciences, Araraquara 14800903, Brazil.
Jean Leandro Dos SantosSão Paulo State University (UNESP) , Institute of Chemistry, Araraquara 14800060, Brazil.ORCID 0000-0002-2460-2829
Funding
Cancer Research UK FC001060NIAID NIH HHS HHSN272201100009CNIAID NIH HHS HHSN272201100009IWellcome Trust
Abstract
Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the infectious disease responsible for the highest number of deaths worldwide. Herein, 22 new N-oxide-containing compounds were synthesized followed by in vitro and in vivo evaluation of their antitubercular potential against Mtb. Compound 8 was found to be the most promising compound, with MIC
Indexed as
AnimalsAntitubercular AgentsBiological AvailabilityCaco-2 CellsHeterocyclic CompoundsHumansMiceMice, Inbred BALB CMicrobial Sensitivity TestsMycobacterium tuberculosisOxidesSpectrum AnalysisAntitubercular AgentsHeterocyclic CompoundsOxides
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.